Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelmastobart - STCube Pharmaceuticals

Next Previous
Drug Profile

Nelmastobart - STCube Pharmaceuticals

Alternative Names: Anti STT-003 antibody; hSTC 810; STC-109; STT 003

Latest Information Update: 26 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator STCube Pharmaceuticals
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; BTN1A1 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 20 Aug 2026 Adverse events data from a phase II trial in Non-small cell lung cancer released by STCube Pharmaceuticals
  • 29 May 2026 Efficacy and adverse events data from a phase-I/II clinical trials in Colorectal cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 10 Jan 2026 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in South Korea (IV) (NCT07306624)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top